Back to Directory

Cheryl Blanchette

Email

ccokley@fhi360.org

Phone

(919) 544-7040 x11359

Institution

FHI 360

Address

FHI360
359 Blackwell Street
Suite 200
Durham, NC 27701

Request an Update

Affiliated Studies

IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum

DAIDS Number

Research Area

Study Status

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected Children >2 to <12 years of age and weighing >10 kgs and <50 kgs

DAIDS Number

Research Area

Study Status

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

Research Area

Study Status

P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants

DAIDS Number

Research Area

IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

Show All